The biggest private biotech investments in October 2023
Welcome to the 65 new subscribers who joined our LinkedIn newsletter last week ?? If not done yet, subscribe to join the 4,675 fans of the Pick of the Week!
Would you like to know who bagged the biggest private biotech investments in October 2023?
Well, last month, U.S.-based Aiolos Bio claimed the top spot, after receiving $245 million in Series A funding to advance its lead drug candidate for asthma into a phase 2 clinical trial.
Meanwhile, second place went to another U.S. company, MapLight Therapeutics, Inc. , and third place went to Belgian firm Agomab .?
Plus, there were plenty of other companies that also managed to raise big rounds, both inside and outside of the healthcare sector.?
However, it’s worth noting that the Asia-Pacific region did lag behind the U.S. and Europe last month in terms of fundraising.
To find out more, read the full article: "The biggest private biotech investments in October 2023"
?? More noteworthy articles from this week:
领英推荐
There is hope that a rich biotech pipeline will produce a second generation of PI3K drugs - which work by inhibiting a pathway that plays a role in cell metabolism, growth, proliferation and survival that has become dysregulated in almost all human cancers - after issues with the first generation from the class had brought up concerns.
The clinical benefits AI has brought to the biopharma industry are hard to ignore, and it’s for this reason that French pharma giant Sanofi has spent the last two years betting big on the technology through a string of drug discovery and development deals with multiple AI companies.
BioTechX 2023, one of Europe’s largest conventions, which blends diagnostics, precision medicine and digital transformation in the field of healthcare, took place in the biotech hub of Basel, Switzerland, from October 4 to 6, providing multiple highlights.
Infectious disease companies began to attract attention during the COVID-19 pandemic, and, now, in a bid to tackle pathogenic outbreaks, many of these biotech companies are ahead of the game, taking their drug and vaccine candidates to the clinic.
??Enjoying these articles??Never miss a single publication of Labiotech by becoming a part of our community!?Click here?to join our mailing list.